Research: Asahi’s Direct R&D on Botanicals and Nootropics

Summary

This document analyzes asahi-group-holdings’s strategic pivot toward health, wellness, and functional ingredients to offset the decline in traditional alcohol consumption. It highlights that Asahi’s proprietary R&D—driven by its independent subsidiary asahi-quality-and-innovations-aqi—focuses overwhelmingly on microbiota, lactic acid bacteria, and yeast derivatives rather than the direct cultivation of botanical adaptogens.

AQI utilizes a backcasting methodology, analyzing projected 2050 megatrends to dictate current research themes. Key proprietary ingredients include lactobacillus-gasseri-cp2305 (for stress and sleep), bacteroides-uniformis (for physical endurance), and yeast-mannan (for sleep and bowel habits).

To compete in the broader functional beverage market and execute functional-premiumization, Asahi relies on a strategic B2B partnership with adm-wild-valencia. In 2024, ADM secured exclusive rights to distribute Asahi’s CP2305 globally. In return, Asahi gains access to ADM’s botanical extracts and taste modulators, enabling effective ingredient-stacking in its own adult-soft-drinks while navigating the clinical-substantiation-gap associated with adaptogens.

Key Findings

• R&D Pivot: Traditional premiumization is insufficient; Asahi is heavily investing in health and wellness R&D to support its multi-beverage strategy.
• Biotics over Botanicals: Asahi’s proprietary IP is in biotics and yeast, not botanical nootropics.
• The B2B Ecosystem Play: The partnership with ADM is a two-way street, scaling Asahi’s biotics globally while providing Asahi with the botanicals needed for its consumer products.